David F. Hale and Ivor Royston, M.D. Join Biocept Board The Board of Biocept, Inc. announced today that David F. Hale has joined the Board as Executive Chairman and Ivor Royston, M.D. as a Director. Mr. Hale and Dr. Royston first worked together at Hybritech, San Diego’s first biotech company, of
Biocept, Inc. Announces New Director Appointment Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Bruce E. Gerhardt as Director. “We are pleased to welcome Bruce to our Board. His experience will be invaluable to us as we move into our next stage of
Biocept Looking to Redefine CTC Dx Market, Plans Product Launch In the midst of a $5 million financing round, microfluidics company Biocept is looking to launch its first diagnostic test, as it embarks on “redefining what a circulating tumor cell is.” Thirteen years after its founding, and
Biocept, Inc. Pioneers Revolutionary Diagnostics Aimed at Personalized Cancer Management We noted earlier this week that San Diego?based Biocept, which is developing advanced cancer diagnostics technology, had recently raised $2.3 million from its investors.
Biocept, Inc. Announces Two New Director Appointments Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today the appointment of Daniel H. Petree and M. Faye Wilson as Directors. “We are pleased to welcome Dan and Faye to our Board.
Biocept Awarded Accreditation by the College of American Pathologists Biocept, Inc. (“Biocept”), an emerging leader in biotechnology, announced today their CLIA laboratory has been awarded accreditation by the Commission on Laboratory Accreditation of the College of American Pathologists (CAP),
